OncoMatch/Clinical Trials/NCT04884035
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Is NCT04884035 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for lymphoma, b-cell.
Treatment: CC-220 · Rituximab · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone · CC-99282 · Polatuzumab vedotin · Rituximab — This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L or ≥ 1.0 x 10^9/L with >50% bone marrow involvement, without growth factor support for 7 days (14 days if peg-G-CSF); Hemoglobin ≥ 8 g/dL; Platelets ≥ 75 x 10^9/L or ≥ 50 x 10^9/L with >50% bone marrow involvement, without transfusion for 7 days.
Kidney function
Estimated serum creatinine clearance (CrCl) of ≥ 50 mL/min using MDRD formula.
Liver function
AST/SGOT and ALT/SGPT ≤ 2.5 x ULN; ≤ 5.0 x ULN if documented liver involvement by lymphoma. Serum total bilirubin ≤ 2.0 mg/dL except in cases of Gilbert's syndrome, then ≤ 5.0 mg/dl. For polatuzumab vedotin: serum total bilirubin < 1.5 × ULN (26 μmol/L), except in cases of Gilbert's syndrome, then ≤ 3.0 mg/dl (51 μmol/L).
Cardiac function
Left ventricular ejection fraction (LVEF) < 45% as determined by MUGA or ECHO is exclusionary.
Participants must have the following laboratory values: ... (see above for details). Impaired cardiac function or clinically significant cardiac disease, including any of the following: LVEF < 45% as determined by MUGA or ECHO.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic - Arizona · Scottsdale, Arizona
- Local Institution - 169 · Duarte, California
- Mayo Clinic - Jacksonville · Jacksonville, Florida
- Mayo Clinic Jacksonville - PPDS · Jacksonville, Florida
- University Of Kansas Medical Center · Kansas City, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04884035 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages